IP Library › Granted Patent US 8,052,974
Granted Patent B2
US 8,052,974 · App. 11/919,265 · Granted Nov 8, 2011

Host cell specific binding molecules capable of neutralizing viruses and uses thereof

Assignee: Crucell Holland B.V.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,052,974
App. No.
11/919,265
Granted
Nov 8, 2011
Kind
B2
Abstract

The present invention provides human binding molecules specifically binding to a host cell protein and having virus neutralizing activity, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and/or treatment of viral infections.

Claims (9)

1. A composition comprising a monoclonal antibody able to bind West Nile Virus and comprising a heavy chain and a light chain,

wherein said heavy chain comprises the CDR1 region according to SEQ ID NO:7, the CDR2 region according to SEQ ID NO:8, and the CDR3 region according to SEQ ID NO:5; and

wherein said light chain of the encoded monoclonal antibody comprises the CDR1 region according to SEQ ID NO:9, the CDR2 region according to SEQ ID NO:10, and the CDR3 region according to SEQ ID NO:11.

2. The composition of claim 1 , wherein the monoclonal antibody further comprises at least one tag.

3. A nucleic acid molecule encoding a monoclonal antibody wherein the heavy chain of the encoded monoclonal antibody comprises the CDR1 region of SEQ ID NO:7, the CDR2 region of SEQ ID NO:8, and the CDR3 region of SEQ ID NO:5; and

wherein the light chain of the encoded monoclonal antibody comprises the CDR1 region of SEQ ID NO:9, the CDR2 region of SEQ ID NO:10, and the CDR3 region of SEQ ID NO:11.

4. The composition of claim 1 , further comprising at least one pharmaceutically acceptable excipient.

5. A method of diagnosing and/or treating an infection caused by West Nile Virus in a subject, the improvement comprising:

utilizing the composition of claim 1 in the diagnosis, prophylaxis, diagnosis and/or treatment of the West Nile Virus infection in the subject.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2007
From: THROSBY, MARK; DE KRUIF, CORNELIS A.
To: CRUCELL HOLLAND B.V.
Reel/Frame 020066/0822 →
Priority Claims (4)
WO PCT/EP2005/052160 · May 12, 2005 · international
WO PCT/EP2005/052648 · Jun 8, 2005 · international
WO PCT/EP2005/052946 · Jun 23, 2005 · international
WO PCT/EP2005/054002 · Aug 15, 2005 · international
Continuity (1)
Related Publication 20100303801A1 · Dec 2, 2010